PMS88 Productivity Loss Due to Low Back Pain: Results from Swedish Registers  by Jonsson, E et al.
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  A649
care expenses concerning osteoarthritic patients decreases during the semester 
following a spa therapy.
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Objectives: This study aimed to evaluate the trajectory of losses to paid produc-
tion in patients with low back pain with/without radiant pain (LBP) before and after 
the start of the condition onset, and before and after surgery for LBP. MethOds: 
Patients visiting healthcare providers, or receiving health insurance benefits, with a 
LBP-diagnosis in region of Västra Götaland in 2008-2012 were identified in the VEGA 
database, along with patients who underwent surgery during 2000-2012, identi-
fied from the national spine surgery register “SWESPINE”. Data from additional 
Swedish national registers including inpatient and outpatient care, drug prescrip-
tions, socioeconomics and social security were extracted. Days of sick leave and 
early retirement were summed and multiplied with the per-day gross wage to obtain 
total cost. Two patient-groups were created and analysed separately; those who 
did not undergo surgery and those with surgery. Patients without surgery were 
followed for 3 years before/after the “onset-date”, defined as the first observed 
event with a specific LBP-diagnosis, and patients with surgery 3 years before/after 
surgery date. Results: More than 145,000 patients were identified. In patients 
who did not undergo surgery, monthly productivity cost gradually increased dur-
ing the 1-12 months pre-onset date, peaking at 1 month post-onset date (€ 1,995), 
levelling at a rate higher in the 12-36 months post-onset (average € 1,022/month) 
compared to 12-36 months pre-onset (average € 605/month). In the surgery-group, 
a similar trajectory was found; on average € 1,345/month in the 12-36 months pre-
surgery, peaking at 1 month post-surgery (€ 2,920), levelling at € 1,469/month in 12-36 
months post-surgery. Women showed higher productivity cost than men, as well 
as older patients compared to younger. cOnclusiOns: Indirect costs related to 
LBP are high. Interventions with the potential of improving treatment of LBP can 
be expected to reduce the burden of disease. Acknowledgements: The study was 
financed with an unrestricted grant from Medtronic.
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Objectives: The aim of this study was to examine the impact of etanercept (ETN) 
therapy on work productivity in patients with rheumatoid arthritis (RA), psoriatic 
arthritis (PsA) and psoriasis (PS), who are not responding to disease-modifying 
antirheumatic drugs (DMARDs) in prospective real world observation in the Czech 
Republic. The data collection is still ongoing. MethOds: Work productivity was 
examined in 17 working patients (6-RA, 8-PsA and 6-PS) using the Health and Work 
Productivity Questionnaire (HPQ) before ETN treatment initiation and after 3 months 
of treatment. Productivity losses were monetized using average wage calculated by 
friction cost (FC) and human capital (HC) approaches. We also measured health-
related quality of life (HRQoL) using the EQ-5D-3L questionnaire. Results: The 
baseline values of absenteeism (Ab), presenteeism (Pr) and total HPQ score were 
0.062, 0.754 and 0.693, respectively. Ab decreased to 0.000 while Pr and total HPQ 
score significantly increased to 0.899 (p = 0.0456 and 0.006) after 3 months of treat-
ment. The average productivity loss per patient was € 1,705 (FC) or € 38,819 (HC) at 
the baseline and it decreased to € 573 (FC) or € 12,971 (HC) after the three months 
of ETN therapy. The largest change in total HPQ score was 0.211 in RA (PsA-0.197, 
PS-0.166). Consequent changes in productivity losses were equal to -€ 1,175 (FC) 
or -€ 25,495 (HC) in RA, -€ 1,062 (FC) or -€ 16,536 (HC) in PsA, and -€ 921 or -€ 35,743 
(HC) in PS. The 3-months ETN therapy also significantly increased the HRQoL: the 
baseline EQ-5D-3L index of 0.659 increased to 0.880 (p< 0.001) and EQ-VAS score of 
39.5 increased to 70.9 (p< 0.001). cOnclusiOns: Modern biological anti-TNF 
(etanercept) therapy has proved to substantially decrease the negative effect of RA, 
PsA and PS on patients’ work productivity leading to lower productivity costs and 
also improvement of theirs quality of life.
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Objectives: The objective of this study was to describe the real-world use of 
rituximab, specifically through examining dispensing frequency among patients 
with rheumatoid arthritis (RA) in England. MethOds: A longitudinal, retrospective 
cohort study was conducted using the Hospital Treatment Insights (HTI) database, 
which links pseudonymised patient data with hospital pharmacy dispensing. HTI 
includes data from January 2010 to September 2014. Included patients were adults 
with RA, defined using ICD-10 codes, who received ≥ 4 dispenses (2 courses) of 
rituximab, with the first course completed within 4 weeks of the index dispense. In 
line with the Summary of Product Characteristics for rituximab, patients must have 
received 1000mg at the index dispense. Any patient with a diagnosis of haematologi-
cal cancer at or prior to index was excluded. Results: One thousand three hundred 
and eighty-one patients had sufficient data to determine dispensing frequency. 
The majority of included patients were female (78.9%), aged 53 and above (60.8%), 
and were dispensed rituximab by a rheumatologist (where consultant type could 
be identified). Two courses of rituximab was the most common number of courses 
received, though some patients received up to 7 courses. The median time between 
courses was found to change with subsequent courses, decreasing from 37.0 weeks 
Objectives: Telerehabilitation after Total Knee Replacement (TKR) showed to be 
not inferior to standard rehabilitation (SR) in clinical outcomes in patients without 
complication related to TKR surgery. Both utilities and cost-utilities are currently 
unexplored for telerehabilitation. The aim of this economic evaluation was to assess 
the potential cost-utility of a mixed telerehabilitation-SR (TR-SR) versus SR pro-
gramme. MethOds: A Markov model simulated the natural progression of TKR, 
assuming telerehabilitation is not influencing transition probabilities and HRQOL. 
Revision risk and utilities were calculated from patient-level data from the multicen-
tre KAT trial, respectively employing parametric survival and linear regression mod-
els. Published literature provided the remaining state-transition probabilities; while 
rehabilitation and transportation costs were identified adopting Ita-NHS perspective 
and monetized employing Italian tariffs. The patients without complication were 
assigned to the TR-SR programme and received half of the sessions in SR and half 
in telerehabilitation regime. Patients with any complication followed the SR. Costs 
and effects were adjusted applying half-cycle correction and an annual discount rate 
of 3%. Probabilistic sensitivity analysis (PSA) described the parameters uncertainty 
and one-way sensitivity analysis assessed the robustness of our assumption for 
HRQOL. Results: Both SR and TR-SR were assessed using a cohort of 1000 patients 
with the KAT trial features (70 years old, 44% male and 19% had any complication). 
The mean±95%CI difference between TR-SR and SR was -215.33±€ 10.64 (the mean 
(SE) lifetime healthcare costs were € 1,033.81 (€ 21.97) for SR and € 818.44 (€ 13.82) for 
SR-TR). The mean (SE) lifetime QALY was 9.69 (0.003). If telerehabilitation at least 
will not decrease the utilities observed in SR, the probability that telereahabilita-
tion is cost-saving (WTP:0€ per QALY) is 90%. cOnclusiOns: SR-TR could be cost-
effective for the Ita-NHS if it does not impair the patients’ HRQOL. Specific utilities 
for telerehabilitation after TKR and further sensitivity analyses are required to relax 
our assumptions.
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Objectives: Campylobacteriosis is one of the most important human foodborne 
infections, attributed to broiler chicken consumption in about 30% of cases. In a 
recently published cost-utility model of potential Campylobacter control measures 
in the EU-27, model assumptions on disease burden and cost of illness were driven 
by data from the Netherlands. The aim of our work was to gather country-specific 
cost of illness estimates, to generate a conservative estimate of Campylobacter 
related disease burden expressed in QALYs, and to re-assess the cost-effectiveness 
of control measure options. MethOds: Data from the Netherlands on productivity 
loss and direct healthcare costs were corrected for country-specific gross average 
wages and total health expenditure per capita, respectively. Health burden due to 
acute gastroenteritis, Guillain-Barré syndrome, and reactive arthritis were estimated 
from published data. Inflammatory bowel disease and irritable bowel syndrome 
were omitted, in line with a WHO opinion. Results: Based on the adapted model, 
the EU-wide implementation of the available and acceptable measures against 
Campylobacter in indoor broiler chicken would be a dominant strategy as com-
pared to the current practice, yielding 26400 QALY gain and 85 million EUR cost 
saving each year. The expected cost saving is due to the decrease of productivity 
loss (69%) and direct healthcare costs (31%). As the investigated strategy is not to 
be reimbursed by healthcare payers, the societal perspective is justified. The poster 
also presents a strategic pricing exercise on bacteriocin treatment in the UK and in 
Hungary (an intervention option currently under development). cOnclusiOns: 
Implementation of the investigated control strategy would be dominant at the EU-27 
level. The cost-effectiveness of add-on bacteriocin treatment in the UK could not be 
justified at the assumed price level. Public health, and also the allocative efficiency 
of public health budgets, could benefit from the application of HTA methodology 
in food safety and nutritional policies.
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Objectives: To describe the cost of ambulatory health care expenses of osteo-
arthritic patients before and after a spa therapy between 2006 to 2011 among the 
French state employees. MethOds: The study is based on patients covered by 
Mutualité de la Fonction Publique Services (MFPS) Health Insurance Company. All 
patients older than 49 years, treated with a spa therapy during 2006-2011 period 
and who have not been treated by spa therapy since at least 2 years were selected 
and considered as « new spa-goers ». The study focused on « osteoarthritic patients 
» defined as those treated by a physiotherapist and/or a rheumatologist during the 
semester before the spa therapy. Data came from MFPS database used to manage 
the reimbursement of health care expenses. Data were collected on a monthly 
basis: medical and paramedical fees, drugs expenses, biological and X-Ray fees. All 
expenses aggregated costs met by National Health Insurance Company (CNAMTS), 
Complementary Health Insurance Company and patients. Statistical analysis were 
done using Stata v11 software. The expenses distribution were compared using 
the Wilcoxon test (p value < 0.05). Results: Among 10,540 patients treated by spa 
therapy, 4,429 osteoarthritic patients (8,072 spa therapy) were selected. The mean 
level of expenses was 1,714.86 € during the semester before and 1,529.33 € after 
the spa therapy (p< 0.001). This decrease (-185.53 € , -10.8%) concerns physiothera-
pists fees (- 93.77 € , -41.7%), drugs expenses (-26.70 € , -5.1%), rheumatologists fees 
(-15.63 € , -42.2%), X-Ray (-17.68 € , -19.7%), GPs fees (-13.33 € , -7.1%) and neurolo-
gists fees (-1.66 € , -26.9%). These decreases are greater among the 50-64 years old 
(-219.58 € , -13.7%) and after the first spa therapy (-206.92 € , -12.8%), but remains 
significant after next spa therapy. cOnclusiOns: In France, ambulatory health 
